drugset / Trial / NCT06585319

Pirfenidone LP or Collagen-polyvinylpyrrolidone in COVID-19

NCT06585319

Phase 2/3 Completed 36 enrolled Materno-Perinatal Hospital of the State of Mexico
RandomizedParallel-groupSingle-blindTreatment

Summary

Collagen-polyvinylpyrrolidone (collagen-PVP) and pirfenidone have the ability to control cytokine storms. This work explores the therapeutic effects of both, on the early treatment of patients with severe COVID-19. The hospital stay, quick COVID-19 severity index (qCSI) and admission to the ICU were statistically significantly lower when the patients were treated with collagen-PVP or pirfenidone, compared to the controls treated with dexamethasone alone.

Timeline

Start
2020-02-01
Primary completion
2021-06-30
Completion
2024-08-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Collagen-Polyvinylpyrrolidone Protein / enzyme biologic 2 ml Intramuscular
Comparator Pirfenidone Small molecule 1200 mg Oral

Indications